MEDSIR IS AN INTERNATIONAL COMPANY THAT FOCUSES ON THE DESIGN, DEVELOPMENT, AND MANAGEMENT OF INDEPENDENT AND COLLABORATIVE RESEARCH IN ONCOLOGY. THE COMPANY’S MAIN GOAL IS TO CONTRIBUTE TO THE CLINICAL DEVELOPMENT OF INNOVATIVE TREATMENTS FOR CANCER PATIENTS.
SCIENCE, STRATEGY, AND PATIENT NEEDS, TOGETHER
In 2012, breast cancer KOLs and experts in clinical development Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Carlos Barrios, Dr. Sunil Verma and María Campos founded MEDSIR (Medica Scientia Innovation Research) with the goal to professionalize independent clinical research in oncology ensuring that the best ideas would be strategically developed and managed in an efficient way while complying with industry quality standards.
MEDSIR started as a company that encouraged researchers in breast and gynecological cancer to turn their brilliant research ideas into full clinical trials. By providing a strategic vision and a full support structure to manage investigator-initiated studies and helping to secure the funds needed, we have evolved into a company with a world-wide network of pantumoral oncology experts. MEDSIR has perfected a collaborative model for clinical development that brings together the benefits of a CRO-based company-sponsored paradigm and all the advantages of investigator driven clinical research.
OUR VISION AND MISSION
OUR VISION IS TO BECOME THE GO-TO COMPANY FOR GLOBAL CLINICAL RESEARCH WITH THE MOST IMPACT IN DEVELOPING NEW AND EFFECTIVE TREATMENTS IN ONCOLOGY. OUR MISSION IS TO TURN INDEPENDENT AND COLLABORATIVE CLINICAL RESEARCH INTO AN EFFICIENT AND STREAMLINED STRATEGY IN CLINICAL DEVELOPMENT.
OF OUR CLINICAL RESEARCH
SHARED-VALUE AS A FUNDAMENTAL WAY OF DOING BUSINESS WHILE ADDING VALUE TO SOCIETY.
Through Critical Thinking, intellectual challenge, and research experience, we strive to develop the best possible clinical trials.
We streamline clinical research to speed up the journey from bench to bedside. Our flexible approach to clinical research knows no borders. Our focus is global.
Patient welfare is always the focal point of our actions, and we strictly comply with regulatory and ethical guidelines.
Diversity and inclusion are crucial both within our company and in our clinical trials.
Integrity, trust, and mutual respect are core to our everyday activities, both internally and with our partners.
MEDSIR IN NUMBERS
We have collaborated with over 31 pharmaceutical companies and biotechs.
We have designed and managed over 48 clinical studies, most of which are prospective international clinical trials.
We have a team of more than 88 highly qualified scientific professionals.
MEDSIR has joined forces with over 232 research sites in over 13 countries worldwide.
More than 400 clinical research ideas populate our intellectual pipeline
We have developed and managed clinical trials in many different solid tumors, including breast, lung, prostate and endometrial, and even in rare tumors such as thoracic or penile carcinomas. We have also developed and managed clinical research in diseases outside of oncology, such as COVID-19.
Our headquarters is in Barcelona (Spain), with a subsidiary in New Jersey, USA.